Article
Immunology
Gail L. Rodgers, Cynthia G. Whitney, Keith P. Klugman
Summary: Pneumococcal conjugate vaccine has successfully reduced the burden of disease and provided herd protection for those who cannot be vaccinated. While widely rolled out in poor countries, there are still many unvaccinated children in middle income countries. Solutions being considered include reducing doses and supporting more affordable vaccine sources.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Economics
Lays P. Marra, Ana L. Sartori, Martha S. Martinez-Silveira, Cristiana M. Toscano, Ana L. Andrade
Summary: This study aimed to evaluate the effectiveness of pneumococcal vaccines on otitis media and acute otitis media in children. The results showed that pneumococcal vaccines play an important role in reducing the incidence of otitis media in children.
Article
Immunology
Kristina L. Bajema, Ryan Gierke, Monica M. Farley, William Schaffner, Ann Thomas, Arthur L. Reingold, Lee H. Harrison, Ruth Lynfield, Kari E. Burzlaff, Susan Petit, Meghan Barnes, Salina Torres, Paula M. Snippes Vagnone, Bernard Beall, Tamara Pilishvili
Summary: The incidence of antibiotic-nonsusceptible invasive pneumococcal disease (NS-IPD) has decreased in the United States after the introduction of 7- and 13-valent pneumococcal conjugate vaccines (PCVs). However, there has been an increase in nonvaccine type NS-IPD, particularly among older adults. The use of higher valency PCVs containing the common nonsusceptible serotypes could help further reduce NS-IPD.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Review
Biotechnology & Applied Microbiology
Tracy A. Becerra-Culqui, Lina S. Sy, Zendi Solano, Hung Fu Tseng
Summary: A systematic review of published studies in the U.S. found no new significant safety concerns related to the use of quadrivalent meningococcal conjugate vaccines in various populations. Future research considerations include post-licensure safety evaluation of a new MenACWY product approved in April 2020.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Review
Medicine, General & Internal
Shuo Feng, Julie McLellan, Nicola Pidduck, Nia Roberts, Julian P. T. Higgins, Yoon Choi, Alane Izu, Mark Jit, Shabir A. Madhi, Kim Mulholland, Andrew J. Pollard, Beth Temple, Merryn Voysey
Summary: This systematic review and meta-analysis found differences in immunogenicity and efficacy between pneumococcal conjugate vaccines (PCV13 and PCV10). PCV13 demonstrated higher immunogenicity for specific serotypes and lower risk of seroinfection compared to PCV10. Additionally, a higher antibody response after vaccination was associated with a decreased risk of subsequent infection.
Article
Gastroenterology & Hepatology
Sheena Crosby, Michael J. Schuh, Michelle Becker, Marina Ivanov, Freddy Caldera, Francis A. Farraye
Summary: Patients with inflammatory bowel disease (IBD) have a high risk of developing invasive pneumococcal infection. Pneumococcal vaccination can decrease this risk, and two new vaccines (PCV15 and PCV20) are now recommended for IBD patients who have not received a pneumococcal conjugate vaccine before. This report aims to inform clinicians about the changes in immunization practices and provide guidance on vaccination series for IBD patients.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Biotechnology & Applied Microbiology
Patricia Izurieta, Michael Scherbakov, Javier Nieto Guevara, Volker Vetter, Lamine Soumahoro
Summary: This systematic review evaluated the efficacy, effectiveness, and impact of 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) and 13-valent PCV (PCV13) on otitis media outcomes. Statistically significant reductions in all-cause and complicated otitis media were consistently observed after the introduction of both vaccines. Some studies suggest PHiD-CV may offer better protection against certain otitis media outcomes, highlighting the need for further research in this area.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Larry S. McDaniel, Edwin Swiatlo
Summary: The emergence of COVID-19 has accelerated the development of new vaccine strategies and provided opportunities for reevaluating vaccines for other pathogens, such as Streptococcus pneumoniae. While current pneumococcal vaccines are based on polysaccharides, there is potential in utilizing proteins expressed across all serotypes for more affordable and broadly-protective vaccines.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Immunology
Ron Dagan, Bart Adriaan van der Beek, Shalom Ben-Shimol, Tamara Pilishvili, Noga Givon-Lavi
Summary: The study demonstrates that the 7-valent and 13-valent pneumococcal vaccines are effective in protecting against otitis media caused by specific serotypes, especially serotypes 19F and 19A.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Microbiology
Lucia Fernandez-Delgado, Jordi Camara, Aida Gonzalez-Diaz, Immaculada Grau, Hisashi Shoji, Fe Tubau, Sara Marti, Ma Angeles Dominguez, Jordi Carratala, Jose Yuste, Carmen Ardanuy
Summary: The study in Spain from 2011 to 2019 showed differences in serotype distribution and antimicrobial resistance between age groups and types of pneumococcal pneumonia. Serotypes 3, 19A, 8, and 11A were the most common, with differences in resistance patterns observed based on age and infection type. Vaccine coverages in the recent years ranged from 32% to 69%, highlighting the importance of continuing surveillance and research on the impact of new conjugate vaccines for pneumococcal disease.
Article
Immunology
Ron Dagan, Qin Jiang, Christine Juergens, James Trammel, William C. Gruber, Daniel A. Scott
Summary: This study found that carrier-induced hyporesponsiveness to PCVs is common among infants, varies by serotype, and is influenced by the timing of carriage acquisition and the number of PCV doses administered. The immune response was consistently lower for certain serotypes carried before or at the time of vaccination, while other serotypes did not generally affect immune responses. Additionally, the study identified a complex interrelationship between carriage and immune response among cross-reacting serotypes.
CLINICAL INFECTIOUS DISEASES
(2021)
Review
Immunology
Bruce A. Mungall, Bernard Hoet, Javier Nieto Guevara, Lamine Soumahoro
Summary: The pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV/PCV10) and 13-valent pneumococcal conjugate vaccine (PCV13) have high effectiveness in preventing vaccine-serotype invasive pneumococcal disease (VT IPD), but vaccine failures and breakthrough cases can still occur, with low rates reported. The main serotypes associated with vaccine failure/breakthrough vary between PCV13 and PCV10.
EXPERT REVIEW OF VACCINES
(2022)
Article
Medicine, General & Internal
Rajeka Lazarus, Sarah Baos, Heike Cappel-Porter, Andrew Carson-Stevens, Madeleine Clout, Lucy Culliford, Stevan R. Emmett, Jonathan Garstang, Lukuman Gbadamoshi, Bassam Hallis, Rosie A. Harris, David Hutton, Nick Jacobsen, Katherine Joyce, Rachel Kaminski, Vincenzo Libri, Alex Middleditch, Liz McCullagh, Ed Moran, Adrian Phillipson, Elizabeth Price, John Ryan, Russell Thirard, Rachel Todd, Matthew D. Snape, David Tucker, Rachel Lauren Williams, Jonathan S. Nguyen-Van-Tam, Adam Finn, Chris A. Rogers
Summary: This study assessed the safety of concomitant administration of COVID-19 and influenza vaccines. The results showed that simultaneous vaccination with ChAdOx1 or BNT162b2 and an age-appropriate influenza vaccine raised no safety concerns and did not adversely affect immune responses.
Article
Immunology
Penina Haber, Jacqueline Tate, Paige L. Marquez, Pedro L. Moro, Umesh Parashar
Summary: The introduction of two live, oral rotavirus vaccines in the US in 2006 and 2008 has led to routine immunization programs. No unexpected adverse events were identified among individuals aged >= 8 months receiving the vaccines. Healthcare providers should adhere to the recommended schedule, and older individuals should take necessary precautions to prevent potential secondary exposure.
Article
Immunology
Stephane B. Dion, Maria Major, Ana Gabriela Grajales, Rajeev M. Nepal, Alejandro Cane, Bradford Gessner, Jelena Vojicic, Jose A. Suaya
Summary: Research in Canada showed that publicly funded pneumococcal vaccine PCV13 significantly reduced IPD cases, but there are still substantial proportions of PCV13-serotype IPD cases in all age groups, indicating limitations to indirect protection provided by the pediatric PCV13 program. Higher-valent PCVs have the potential to address a substantial proportion of remaining IPD cases among all age groups.